CABERGOLINE

Cabergoline is a dopamine agonist reducing prolactin levels and treating pituitary disorders. Side effects include nausea, dizziness, and impulse‑control changes.

SKU: fc0f5024d613 Category: Tag:

Product Description


Mechanism of action

Cabergoline is a long-acting dopamine D₂ receptor agonist that powerfully suppresses prolactin secretion from pituitary lactotrophs. It reduces intracellular cAMP, inhibits prolactin gene transcription and restores dopaminergic tone. It also affects nigrostriatal dopaminergic pathways.

Benefits and advantages

Used in prolactin-regulation research, pituitary-adenoma studies, dopaminergic signalling analysis, Parkinsonism modelling and ergoline SAR investigations.

Side effects and risks

Risks include nausea, hypotension, valvulopathy (with chronic use), dizziness, hallucinations and impulse-control disturbances. Handle under dopaminergic-agonist precautions.

Datasheet


Molecular Formula

C26H37N5O2

Molecular Weight

451.6 g/mol

CAS Number

81409-90-7

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Insoluble

Purity

Purity information is available upon request (COA).

Synonym

cabergoline; 81409-90-7; Dostinex; Cabaser; Cabergolina

IUPAC/Chemical Name

(6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide

InChl Key

KORNTPPJEAJQIU-KJXAQDMKSA-N

InChl Code

InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/54746;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download